Telik, Inc. (NASDAQ:TELK) is seeing shares surging pre-market after it announced that the U.S. Food and Drug Administration has removed the partial hold on TELCYTA clinical trials after a complete review of TELCYTA data by the agency and permits the resumption of TELCYTA clinical development.
This is Telik’s most advanced development program, a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non- small cell lung cancer. Its other development candidate that is considered an advanced candidate is TELINTRA in clinical development for the treatment of myelodysplastic syndrome.
As of Friday’s close at $3.46, Telik had a $181.8 million market capitalization. Shares are up over 15% pre-market at $4.05. The 52-week trading range is $2.55 to $20.36, so you can see the reason for the large push pre-market. It trades an average of about 370,000 shares in any given day, but as of the end of September its short interest was more than 9.4 million shares. This sounds like there will be lots of short covering this morning.
Jon C. Ogg
October 15, 2007
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
